Please use this identifier to cite or link to this item: https://repositorio.uca.edu.ar/handle/123456789/10188
Título : Therapeutical implications of melatonin in alzheimer’s and parkinson’s diseases
Autor : Cardinali, Daniel Pedro 
Vigo, Daniel Eduardo 
Olivar, Natividad 
Vida, María F. 
Brusco, Luis I. 
Palabras clave : NEURODEGENERACIONRADICALES LIBRESESTRES OXIDATIVOENVEJECIMIENTOENFERMEDAD DE ALZHEIMERCOGNICIONMELATONINA
Fecha de publicación : 2015
Editorial : Humana Press
Cita : Cardinali, D. P., et al. Therapeutical implications of melatonin in alzheimer’s and parkinson’s diseases [en línea]. En: Engin, A., Engin, A. (eds.). Tryptophan Metabolism: Implications for Biological Processes, Health and Disease. Humana Press: Cham, 2015. doi:10.1007/978-3-319-15630-9_9 Disponible en: https://repositorio.uca.edu.ar/handle/123456789/10188
Resumen : Abstract: Neurodegenerative diseases like Alzheimer’s disease (AD) and Parkinson’s disease (PD) are major health problems, and a growing recognition exists that efforts to prevent them must be undertaken by both governmental and nongovernmental organizations. In this context, the pineal product melatonin has a promising significance because of its chronobiotic/cytoprotective properties. One of the features of advancing age is the gradual decrease in endogenous melatonin syn- thesis. A limited number of therapeutic trials have indicated that melatonin has a potential therapeutic value as a neuroprotective drug in the treatment of AD, mini- mal cognitive impairment (which may evolve to AD), and PD. Both in vitro and in vivo, melatonin prevented the neurodegeneration seen in experimental models of AD and PD. For these effects to occur, doses of melatonin about two orders of mag- nitude higher than those required to affect sleep and circadian rhythmicity are needed. More recently, attention has been focused on the development of potent melatonin analogs with prolonged effects which were employed in clinical trials in sleep-disturbed or depressed patients in doses considerably higher than those employed for melatonin. In view that the relative potencies of the analogs are higher than that of the natural compound, clinical trials employing melatonin in the range of 50–100 mg/day are needed to assess its therapeutic validity in neurodegenerative disorders.
URI : https://repositorio.uca.edu.ar/handle/123456789/10188
ISBN : 978-3-319-15630-9 (online)
978-3-319-15629-3 (impreso)
Disciplina: MEDICINA
DOI: 10.1007/978-3-319-15630-9_9
Derechos: Atribución-NoComercial-CompartirIgual 4.0 Internacional
Appears in Collections:Libros o partes de libro

Files in This Item:
File Description SizeFormat
therapeutical-implications-melatonin-alzheimer.pdf1,17 MBAdobe PDFThumbnail
View/Open
978-3-319-15630-9.jfif30,34 kBUnknownView/Open
Show full item record

Page view(s)

74
checked on Sep 2, 2021

Download(s)

141
checked on Sep 2, 2021

Google ScholarTM

Check


Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.